Aptamer Group plc at its general meeting held on August 17, 2023 announced that With effect from 21 August 2023, the board will comprise: · Stephen Hull (Executive Chairman), aged 69 years · Dr Arron Tolley (Chief Technical Officer) · Dr David Bunka (Chief Scientific Officer) · Dean Fielding (Independent Non-Executive Director) · Dr Adam Hargreaves (Independent Non-Executive Director). The resignations of Dr Ian Gilham (Executive Chairman), Dr Rob Quinn (Interim Chief Executive Officer and Chief Financial Officer), Dr John Richards (Non-Executive Director) and Angela Hildreth (Non-Executive Director) take effect from Second Admission (scheduled for 8.00am on 21 August 2023). The Company intends to appoint a Chief Executive Officer when appropriate to do so.

Further information on the new directors and the participation of existing Directors, Proposed Directors and senior managers in the Fundraise, are set out at the end of this announcement. Steve is an experienced company director and entrepreneur, having started, acquired, developed and successfully exited a number of businesses. He was previously chairman of Aptamer Group until the IPO in December 2021.

Arron, aged 45 years is the founder of Aptamer Group and was CEO from 2008 - 2023. Arron holds a Ph.D. in Molecular Biology and Biophysics from the University of Leeds and a B.Sc. in Molecular Medicine.

Arron has over 19 years' experience in the field of nucleic acid biology and has expertise in the development of aptamers against multiple target types, including complex cellular targets in model disease systems. Arron led the growth of the company from a small laboratory built in the basement of his house to a successful aptamer development company. Arron led the business through various stages of growth, and funding, including the AIM IPO in December 2021. Arron has extensive experience in business development, business administration and translational science and holds an honorary professorship for translational science and entrepreneurship from the University of Surrey.

Dean, aged 57 years is an independent non-executive director and chair of the audit committee at The Property Franchise Group plc.  He was previously Group Finance Director of LSL Property Services plc, Finance Director of Your Move and a non-executive director of Hunters Property plc, in addition to a variety of consultancy and other non-executive roles. Dr Adam Hargreaves, aged 44 years is the founder of PathCelerate Limited, a contract research pharmaceutical efficacy and safety company.  Spanning a 20-year career, he previously worked for AstraZeneca, and has interests and skills in preclinical and translational small molecule, biologic, and RNA-based pharmaceuticals.  PathCelerate has provided preclinical and clinical drug discovery and development assistance to a number of global pharmaceutical companies, in addition to a wide and diverse range of small- and medium-sized biotechnology and medical device firms; assisting in the generation of numerous Investigational New Drug and Clinical Trial Application submissions. Adam is a Fellow of the Royal College of Pathologists and is a board-certified Diplomate of the American College of Veterinary Pathology.  His PhD research encompassed oncology medicine safety and he has held posts including President of the British Society of Toxicologic Pathology and Visiting Professor at the University of Surrey, where he lectures in pharmaceutical efficacy and safety.  He is a keen investor in small-cap drug discovery and biotechnology AIM stocks, and takes a particular interest in how such companies attract both retail and institutional investment via portfolio expansion and pertinent news flow.